SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: john douglas who wrote (7528)4/28/1998 12:58:00 PM
From: Colby  Read Replies (1) | Respond to of 23519
 
Oh, am I pissed. I just tried to post a long message that got lost in electronic hell. Spilt milk, I guess.

Anyway, here's a shorter version.
Time magazine's cover this week, THE POTENCY PILL.
It is a good article that is slightly tainted, but it does a good job of pointing out some of the negatives. For example:

1. 1 out of 10 men in the clinical trials developed blinding headaches that grew more severe at higher doses. (That is 10% of the market that probably won't be using Viagra.)

2. 3% develop temporary vision problems.

3. Viagra can trigger sudden drops in blood pressure, and there is a risk that men who take it in combination with nitroglycerin or other antihypertensive drugs could faint or go into shock. (Many potential Viagra users are probably on at least one drug, if not more. Again, a positive for VVUS.

All in all, a pretty fair article.

The remaining post has nothing to do with the article.

The amount of free PR the ED market has been getting has been unbelievable. Viagra is certainly going to be the granddaddy, but there will be a ton of overflow for the other guys, like our VVUS.

I like the way the stock is holding. I will not be surprised if it falls back, but that won't concern me too much either. Also, I think the new Rx's will be down longer than people think. I am saying a month or so, maybe longer (I prefer to be conservative, that way if there is a surprise, most likely it is postive). All just the opinion of this man.

Standing erect,
Colby



To: john douglas who wrote (7528)4/28/1998 2:06:00 PM
From: Diamondcutter  Read Replies (2) | Respond to of 23519
 
All of the consensus forecasts are as recent as the analyst updates them.

First Call has 2Q @ -$0.04 and the full year at +$.38 from 6 analysts. 1999 has three estimates averaging +$1.44. FYI the five estimates in 1998 are from First Boston (+0.62), Wessels Arnold (+$0.46), PaineWebber (+0.45), Genesis (+0.34), Cruttendon (+0.30), and DRW (+0.18).

Diamondcutter